trial · primary record
Sacituzumab Tirumotecan (SKB264)
Penile Squamous Cell Carcinoma (PSCC)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 31 |
| Primary completion | 2030-01-01 |
| Primary endpoint | Objective Response Rate (ORR) per RECIST 1.1 |
| Registry ID | NCT07907861 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:42:04.211Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07907861
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Sacituzumab tirumotecan · compound